These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 33502734)

  • 1. WT1-specific CD8 + cytotoxic T cells with the capacity for antigen-specific expansion accumulate in the bone marrow in MDS.
    Suwabe T; Shibasaki Y; Sato H; Tamura S; Katagiri T; Nemoto H; Kasami T; Kozakai T; Nanba A; Kitajima T; Fuse K; Ushiki T; Sone H; Narita M; Masuko M
    Int J Hematol; 2021 May; 113(5):723-734. PubMed ID: 33502734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
    Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
    Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.
    Tanaka-Harada Y; Kawakami M; Oka Y; Tsuboi A; Katagiri T; Elisseeva OA; Nishida S; Shirakata T; Hosen N; Fujiki F; Murao A; Nakajima H; Oji Y; Kanda Y; Kawase I; Sugiyama H
    Cancer Sci; 2010 Mar; 101(3):594-600. PubMed ID: 20132220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organ.
    Murao A; Oka Y; Tsuboi A; Elisseeva OA; Tanaka-Harada Y; Fujiki F; Nakajima H; Nishida S; Hosen N; Shirakata T; Hashimoto N; Myoui A; Ueda T; Takeda Y; Osaki T; Enomoto T; Yoshikawa H; Kimura T; Oji Y; Kawase I; Sugiyama H
    Cancer Sci; 2010 Apr; 101(4):848-54. PubMed ID: 20136847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].
    Lu D; Qin YZ; Li LD; Shi HX; Lai YY; Liu YR
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):370-6. PubMed ID: 24763007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma.
    Tsuboi A; Oka Y; Nakajima H; Fukuda Y; Elisseeva OA; Yoshihara S; Hosen N; Ogata A; Kito K; Fujiki F; Nishida S; Shirakata T; Ohno S; Yasukawa M; Oji Y; Kawakami M; Morita S; Sakamoto J; Udaka K; Kawase I; Sugiyama H
    Int J Hematol; 2007 Dec; 86(5):414-7. PubMed ID: 18192109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy.
    Sloand EM; Melenhorst JJ; Tucker ZC; Pfannes L; Brenchley JM; Yong A; Visconte V; Wu C; Gostick E; Scheinberg P; Olnes MJ; Douek DC; Price DA; Barrett AJ; Young NS
    Blood; 2011 Mar; 117(9):2691-9. PubMed ID: 21097671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
    Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
    Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Ishikawa T; Fujii N; Imada M; Aoe M; Meguri Y; Inomata T; Nakashima H; Fujii K; Yoshida S; Nishimori H; Matsuoka KI; Kondo E; Maeda Y; Tanimoto M
    Cytotherapy; 2017 Apr; 19(4):514-520. PubMed ID: 28139337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.
    Tamaki H; Ogawa H; Ohyashiki K; Ohyashiki JH; Iwama H; Inoue K; Soma T; Oka Y; Tatekawa T; Oji Y; Tsuboi A; Kim EH; Kawakami M; Fuchigami K; Tomonaga M; Toyama K; Aozasa K; Kishimoto T; Sugiyama H
    Leukemia; 1999 Mar; 13(3):393-9. PubMed ID: 10086730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
    Baba M; Hata T; Tsushima H; Mori S; Sasaki D; Turuta K; Hasegawa H; Ando K; Sawayama Y; Imanishi D; Taguchi J; Yanagihara K; Tomonaga M; Kamihira S; Miyazaki Y
    Intern Med; 2015; 54(5):445-51. PubMed ID: 25758068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of bone marrow and peripheral blood immunoregulatory lymphocytes in patients with myelodysplastic syndrome.
    Iwase O; Aizawa S; Kuriyama Y; Yaguchi M; Nakano M; Toyama K
    Ann Hematol; 1995 Dec; 71(6):293-9. PubMed ID: 8534761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Wilms Tumor Protein 1" (WT1) peptide vaccination-induced complete remission in a patient with acute myeloid leukemia is accompanied by the emergence of a predominant T-cell clone both in blood and bone marrow.
    Ochsenreither S; Fusi A; Busse A; Bauer S; Scheibenbogen C; Stather D; Thiel E; Keilholz U; Letsch A
    J Immunother; 2011 Jan; 34(1):85-91. PubMed ID: 21150716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL15 can reverse the unresponsiveness of Wilms' tumor antigen-specific CTL in patients with prostate cancer.
    King JW; Thomas S; Corsi F; Gao L; Dina R; Gillmore R; Pigott K; Kaisary A; Stauss HJ; Waxman J
    Clin Cancer Res; 2009 Feb; 15(4):1145-54. PubMed ID: 19228720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of Wilms' tumor gene peptide-specific cytotoxic T lymphocytes in immunologic selection of a paroxysmal nocturnal hemoglobinuria clone.
    Ikeda K; Shichishima T; Yasukawa M; Nakamura-Shichishima A; Noji H; Akutsu K; Osumi K; Maruyama Y
    Exp Hematol; 2007 Apr; 35(4):618-26. PubMed ID: 17379072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
    Oka Y; Tsuboi A; Murakami M; Hirai M; Tominaga N; Nakajima H; Elisseeva OA; Masuda T; Nakano A; Kawakami M; Oji Y; Ikegame K; Hosen N; Udaka K; Yasukawa M; Ogawa H; Kawase I; Sugiyama H
    Int J Hematol; 2003 Jul; 78(1):56-61. PubMed ID: 12894852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies.
    Rosenfeld C; Cheever MA; Gaiger A
    Leukemia; 2003 Jul; 17(7):1301-12. PubMed ID: 12835718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome.
    Zheng Z; Qianqiao Z; Qi H; Feng X; Chunkang C; Xiao L
    Exp Hematol; 2010 Aug; 38(8):677-84. PubMed ID: 20394797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.